Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARTIST: Adaptive RT + Targeted Therapy in NSCLC
NCT02277457Phase 1Withdrawn
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Sep 2015
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of erlotinib and crizotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Progression-Free Survival at 5 years and Overall Survival at 5 years. Planned start Sep 2015; status: withdrawn.
02
Drugs
erlotinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02277457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02277457.